Prohibits prior authorization or a step therapy protocol for the prescription of a nonpreferred medication on their drug formulary used to assess or treat an enrollee's bipolar disorder, schizophrenia or schizotypal.
This bill amends Rhode Island’s medical assistance prescription drug law to bar the Rhode Island medical assistance program, and any managed care organization contracting with it, from requiring prior authorization or step therapy for nonpreferred anticonvulsant and antipsychotic medications on the formulary. In practical terms, it would make it easier for Medicaid enrollees to access certain mental health and seizure-disorder medications without first trying other drugs or obtaining additional approval, while preserving the program’s ability to apply clinical prior-authorization edits and to deny drugs removed from the market for safety reasons.
The bill also requires the state and its Medicaid managed care partners to collect and report detailed utilization and spending data for anticonvulsants and antipsychotics, including claims, rebates, prior authorization requests, step therapy exceptions, approval/denial rates, and generic utilization. In addition, the Department of Health must compile statewide and municipal data on the costs of mental health emergency responses by ambulances, hospitals, police, and fire departments, and the Executive Office of Health and Human Services must submit these reports to legislative leaders and committees by specified deadlines. The act takes effect for policies and contracts on or after January 1, 2026 and sunsets at the end of 2028.
The bill would create a new section in Chapter 40-21 of the General Laws governing medical assistance prescription drugs, directly limiting utilization management tools for Medicaid coverage of nonpreferred anticonvulsant and antipsychotic drugs. It would also require amendments to current and future managed care contracts to ensure compliance, and it authorizes the secretary of the Executive Office of Health and Human Services to seek any necessary federal approval before implementation. The reporting requirements would impose new data-collection obligations on Medicaid administrators and the Department of Health, affecting state agencies, managed care organizations, and municipal public-safety and health-response systems.
The bill appears to have strong support, as reflected by its unanimous passage in the Senate with 37 yeas and 0 nays. The available context suggests a broadly favorable view of reducing barriers to access for medications used to treat serious mental health conditions and seizure disorders, along with interest in better understanding costs and utilization through reporting. No committee transcript is available, so the recorded vote is the main indicator of sentiment.
The main policy issue is whether Medicaid should be prohibited from using prior authorization and step therapy for nonpreferred anticonvulsant and antipsychotic medications. Supporters are likely focused on continuity of care, timely access, and avoiding treatment disruptions for people with bipolar disorder, schizophrenia, schizotypal disorders, and seizure conditions. Potential concerns would center on cost control, formulary management, and the administrative burden of the new reporting requirements, though no explicit opposition is reflected in the available materials. The bill also includes safeguards preserving clinical edits and the ability to deny unsafe drugs, which may address some concerns about overbroad restrictions.